tradingkey.logo

Dynavax Technologies Corp

DVAX
15.380USD
+4.250+38.19%
Close 12/24, 13:00ETQuotes delayed by 15 min
1.81BMarket Cap
LossP/E TTM

Dynavax Technologies Corp

15.380
+4.250+38.19%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Dynavax Technologies Corp

Currency: USD Updated: 2025-12-24

Key Insights

Dynavax Technologies Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 3/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.75.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dynavax Technologies Corp's Score

Industry at a Glance

Industry Ranking
3 / 404
Overall Ranking
24 / 4562
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
20.750
Target Price
+89.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dynavax Technologies Corp Highlights

StrengthsRisks
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -42.28, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 115.83M shares, increasing 0.06% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.10K shares of this stock.

Financial Health

Currency: USD Updated: 2025-12-24

The current financial score of Dynavax Technologies Corp is 8.89, ranking 27/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 94.88M, representing a year-over-year increase of 17.67%, while its net profit experienced a year-over-year increase of 53.05%.

Score

Industry at a Glance

Previous score
8.89
Change
0

Financials

8.03

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

8.65

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.75

Dynavax Technologies Corp's Company Valuation

Currency: USD Updated: 2025-12-24

The current valuation score of Dynavax Technologies Corp is 7.94, ranking 77/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -42.28, which is -504.24% below the recent high of 170.92 and -613.84% above the recent low of -301.83.

Score

Industry at a Glance

Previous score
7.94
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 3/404
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-24

The current earnings forecast score of Dynavax Technologies Corp is 7.50, ranking 283/404 in the Biotechnology & Medical Research industry. The average price target for Dynavax Technologies Corp is 20.50, with a high of 31.00 and a low of 11.00.

Score

Industry at a Glance

Previous score
7.50
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
20.750
Target Price
+89.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Dynavax Technologies Corp
DVAX
4
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-24

The current price momentum score of Dynavax Technologies Corp is 9.72, ranking 4/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 17.04 and the support level at 12.18, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.14
Change
2.58

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.561
Buy
RSI(14)
89.441
Overbought
STOCH(KDJ)(9,3,3)
83.016
Buy
ATR(14)
0.539
High Vlolatility
CCI(14)
466.667
Overbought
Williams %R
2.263
Overbought
TRIX(12,20)
0.141
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
11.880
Buy
MA10
11.348
Buy
MA20
11.172
Buy
MA50
10.846
Buy
MA100
10.500
Buy
MA200
10.772
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-24

The current institutional shareholding score of Dynavax Technologies Corp is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 109.38%, representing a quarter-over-quarter decrease of 3.57%. The largest institutional shareholder is The Vanguard, holding a total of 8.08M shares, representing 6.88% of shares outstanding, with 4.74% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Deep Track Capital LP
15.73M
-11.61%
BlackRock Institutional Trust Company, N.A.
15.80M
-15.27%
The Vanguard Group, Inc.
Star Investors
8.40M
-3.07%
State Street Investment Management (US)
6.40M
-5.81%
Millennium Management LLC
1.61M
+612.12%
Chicago Capital, LLC
5.23M
-2.18%
Dimensional Fund Advisors, L.P.
3.64M
-9.11%
Renaissance Technologies LLC
Star Investors
2.89M
+6.69%
Two Sigma Investments, LP
3.80M
+67.74%
Geode Capital Management, L.L.C.
2.69M
-12.30%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-24

The current risk assessment score of Dynavax Technologies Corp is 7.06, ranking 19/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.94. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
7.96
Change
-0.9
Beta vs S&P 500 index
0.94
VaR
+4.37%
240-Day Maximum Drawdown
+35.00%
240-Day Volatility
+52.89%

Return

Best Daily Return
60 days
+38.19%
120 days
+38.19%
5 years
+38.19%
Worst Daily Return
60 days
-5.80%
120 days
-6.60%
5 years
-22.16%
Sharpe Ratio
60 days
+2.68
120 days
+1.60
5 years
+0.44

Risk Assessment

Maximum Drawdown
240 days
+35.00%
3 years
+37.56%
5 years
+64.42%
Return-to-Drawdown Ratio
240 days
+0.62
3 years
+0.35
5 years
+0.15
Skewness
240 days
+6.02
3 years
+4.75
5 years
+1.34

Volatility

Realised Volatility
240 days
+52.89%
5 years
+54.62%
Standardised True Range
240 days
+2.52%
5 years
+3.45%
Downside Risk-Adjusted Return
120 days
+478.31%
240 days
+478.31%
Maximum Daily Upside Volatility
60 days
+80.35%
Maximum Daily Downside Volatility
60 days
+82.83%

Liquidity

Average Turnover Rate
60 days
+1.35%
120 days
+1.64%
5 years
--
Turnover Deviation
20 days
-2.92%
60 days
-14.44%
120 days
+4.00%

Peer Comparison

Biotechnology & Medical Research
Dynavax Technologies Corp
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
Charles River Laboratories International Inc
CRL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Dynavax Technologies Corp?

The TradingKey Stock Score provides a comprehensive assessment of Dynavax Technologies Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Dynavax Technologies Corp’s performance and outlook.

How do we generate the financial health score of Dynavax Technologies Corp?

To generate the financial health score of Dynavax Technologies Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Dynavax Technologies Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Dynavax Technologies Corp.

How do we generate the company valuation score of Dynavax Technologies Corp?

To generate the company valuation score of Dynavax Technologies Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Dynavax Technologies Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Dynavax Technologies Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Dynavax Technologies Corp.

How do we generate the earnings forecast score of Dynavax Technologies Corp?

To calculate the earnings forecast score of Dynavax Technologies Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Dynavax Technologies Corp’s future.

How do we generate the price momentum score of Dynavax Technologies Corp?

When generating the price momentum score for Dynavax Technologies Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Dynavax Technologies Corp’s prices. A higher score indicates a more stable short-term price trend for Dynavax Technologies Corp.

How do we generate the institutional confidence score of Dynavax Technologies Corp?

To generate the institutional confidence score of Dynavax Technologies Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Dynavax Technologies Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Dynavax Technologies Corp.

How do we generate the risk management score of Dynavax Technologies Corp?

To assess the risk management score of Dynavax Technologies Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Dynavax Technologies Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Dynavax Technologies Corp.
KeyAI